R. Sharifi

发表

Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.

G. Kennealey, G. Chodak, N. Block, 1995, Urology.

Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues

P. Schellhammer, N. Vogelzang, M. Soloway, 1999, The Prostate.

Comparison of goserelin and leuprolide in combined androgen blockade therapy.

P. Schellhammer, E. Klein, N. Vogelzang, 1998, Urology.

Bicalutamide and Flutamide, Each in Combination with Luteinizing Hormone-Releasing Hormone Analogs, in Advanced Prostate Cancer: Exploratory Analysis of Impact of Extent of Disease by Bone Scan on Outcome

P. Schellhammer, N. Vogelzang, M. Soloway, 2000 .

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1997, Urology.

A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1996, European urology.

Erattum: Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial (Urology (September 1997) 50 (330-336))

P. Schellhammer, N. Vogelzang, M. Soloway, 1998 .

Estimated potency of casodex: A problematic design [1] (multiple letters)

P. Schellhammer, J. Simard, N. Vogelzang, 1997 .